Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
In a rat model of autoimmune thyroiditis, TGPL significantly lowered serum TPOAb, TGAb, and TNF- levels while boosting IL-10 levels and ameliorating thyroid follicle damage
Semaglutide is injected once weekly
In this case, Ozempic could be prescribed for weight loss instead of type 2 diabetes
Triple Agonists (GLP-1/GIP/Glucagon) Titration and Tapering Algorithms At a glance Prototype agent / retatrutide (LY3437943), subcutaneous weekly injection Phase 2 peak weight loss / 24.2% at 48 weeks (12 mg cohort, N=338 total trial) Titration duration / 24 weeks across 4 dose steps before reaching maintenance Starting dose / 2 mg subcutaneous once weekly for weeks 1 to 4 Maintenance dose range / 8 mg or 12 mg once weekly depending on tolerability Primary targets / obesity, MASLD, type 2 diabetes, metabolic syndrome GI adverse events / nausea in 53 to 65% of participants at higher dose steps Taper recommendation / dose reduction over 8 to 12 weeks when discontinuing FDA status / Phase 3 (TRIUMPH program) ongoing as of early 2025
.jpg)